摘要
目的:探讨与树突状细胞(dendritic cell,DC)共培养细胞因子诱导的杀伤细胞(cytokine-induced killers,CIK)联合化疗治疗乳腺癌的临床疗效及安全性。方法:选取36例DC-CIK细胞治疗联合化疗的乳腺癌患者,同期临床特点相近的病例26例作为对照组接受单纯化疗,比较两组患者治疗后细胞免疫功能、近期疗效、生存质量等,并观察DC-CIK细胞治疗的安全性。结果:DC-CIK联合化疗治疗的患者,外周血液中CD3+、CD4+细胞及NK细胞比率显著高于单纯化疗组,差异有统计学意义(P<0.05);DC-CIK+化疗组治疗总有效率(RR)未见明显差异(P>0.05),疾病控制率(DCR)明显高于单纯化疗组(P<0.05);DC-CIK+化疗组患者中位PFS较单纯化疗组长(P<0.05),两组患者中位OS比较差异无统计学意义(P>0.05);DC-CIK+化疗组在躯体功能、情绪功能、社会功能方面及总体生活质量较治疗前明显改善,且明显好于单纯化疗组(P<0.05)。结论:DC-CIK联合化疗能够显著改善乳腺癌患者的免疫功能,提高疗效,减轻不良反应,延长无进展生存期,改善患者的生活质量。
Objective： To explore the clinical efficacy and safety of cytokine - induced killers induced by dendritic cell eoeulture cytokine （DC - CIK） combined with chemotherapy in treatment of breast cancer. Methods- Thirty - six breast cancer patients treated with DC - CIK combined with chemotherapy were selected ; twenty - six breast cancer patients with the similar clinical characteristics during the same period were selected as control group, and they were treated with simple chemotherapy; the cell immune functions, short -term cura- tive effects, and qualities of life （QOLs） in the two groups were compared, the safety of DC - CIK therapy was observed. Results： The rati- os of CD3 ＋ cells, CD4＋ cells and NK cells in peripheral blood of combined treatment group were statistically significantly higher than those in control group （P 〈 0. 05） ; there was no statistically significant difference in the total effective rate between the two groups （ P 〉 0. 05 ）, the disease control rate （DCR） in combined treatment group was statistically significantly higher than that in control group （P 〈 0. 05 ） ; me- dial progression- free survival （PFS） in combined treatment group was statistically significantly longer than that in control group （P 〈 0. 05 ）, there was no statistically significant difference in medial overall survival （OS） between the two groups （ P 〉 0.05 ） ; in combined treatment group, the physical function, emotion function, social function, and total QOL after treatment were significantly improved compared with before treatment, which were statistically significantly better than those in control group （P 〈 0. 05） . Conclusion： DC -CIK com- bined with chemotherapy can effectively improve the immune function and curative effect, reduce the side effects, prolong the PFS, and im- prove QOL of breast cancer patients.
出处
《中国妇幼保健》
CAS
北大核心
2013年第31期5134-5137,共4页
Maternal and Child Health Care of China
基金
吉林省科技厅重点实验室项目〔20122113〕
